1. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
- Author
-
Liu L, Fei Z, Chen M, Zhao L, Su H, Gu D, Lin B, Cai X, Lu L, Gao M, Ye X, Jin X, and Xie C
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy adverse effects, Female, Humans, Induction Chemotherapy adverse effects, Induction Chemotherapy mortality, Male, Middle Aged, Multivariate Analysis, Nasopharyngeal Carcinoma mortality, Nasopharyngeal Carcinoma pathology, Nasopharyngeal Neoplasms mortality, Nasopharyngeal Neoplasms pathology, Progression-Free Survival, Radiotherapy, Intensity-Modulated adverse effects, Radiotherapy, Intensity-Modulated mortality, Retrospective Studies, Young Adult, Chemoradiotherapy methods, Induction Chemotherapy methods, Nasopharyngeal Carcinoma therapy, Nasopharyngeal Neoplasms therapy, Radiotherapy, Intensity-Modulated methods
- Abstract
Background: In the era of intensity-modulated radiotherapy (IMRT), the role of additional concurrent chemotherapy (CC) to radiotherapy (RT) after induction chemotherapy (IC) compared to IC followed by RT alone remains unclear for stage II-IVB nasopharyngeal carcinoma (NPC) patients. The aim of this study was to evaluate the efficacy and toxicities of IC/RT and IC/CCRT in the treatment of NPC with volumetric modulated arc therapy (VMAT)., Methods: From January 2012 to March 2016, a total of 217 NPC patients were retrospectively assessed. Of the 217 patients, 139 patients received IC followed by VMAT alone and 78 patients received IC plus CCRT. Overall survival (OS), progression-free survival (PFS) and toxicities were assessed., Results: The 5-year OS, PFS rates were 57.5%, 41.8% and 47.8%, 38.4% for the IC/RT and IC/CCRT arms, respectively, without significant difference in survival between the two groups (both p > 0.05). Multivariate analysis indicated that treatment modality (IC/RT vs. IC/CCRT) was not an independent prognostic factor for OS or PFS. Grade 3-4 leukopenia/neutropenia (3.60% vs. 20.51%, p < 0.001), gastrointestinal disorder (nausea/vomiting/diarrhea, 2.16% vs. 41.03%, p < 0.001), mucositis (29.50% vs. 47.44%, p = 0.01) and xerostomia (34.53% vs. 48.72%, p = 0.04) were more frequent in the IC/ CCRT arm than in the IC/RT arm during VMAT., Conclusions: No significant difference in OS and PFS was observed between IC plus VMAT alone and IC/CCRT in the treatment of stage II-IVB NPC patients, however, more side effects were observed in the IC/CCRT arm.
- Published
- 2018
- Full Text
- View/download PDF